PK Study of Anti-TB Drugs
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02457208 |
|
Recruitment Status :
Recruiting
First Posted : May 29, 2015
Last Update Posted : October 10, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tuberculosis | Drug: Isoniazid (H) Drug: Rifampicin (R) Drug: Pyrazinamide (Z) Drug: Ethambutol (E) | Phase 1 |
The threat of tuberculosis and HIV remains as major public health issues all over the world. Multi-drug resistant tuberculosis (MDR TB) is also a rising public health issue. Currently available standardized TB treatment is 6 months in duration. Previous pharmacokinetic and pharmacodynamic (PK/PD) studies of anti-TB drugs have shown that a number of factors such as HIV status, diabetes, malnutrition, age, sex, race, genetics (e.g. NAT2 polymorphisms), drug- drug interactions and food interactions may cause variation of the PK and/or the treatment outcome. But the findings are not persistent from one study to another, for example Chideya S. et al's study in Botswana showed that lower Cmax of anti-TB drugs frequently occurred in TB/HIV coinfected patients and low Cmax of pyrazinamide was related to poor treatment outcomes. On the other hand Requena-Méndez A. et al's study showed the variation of rifampin Cmax was not related to HIV. Large between-patient variability in PK parameters was recently shown to be strongly associated with TB treatment failures and possibly the emergence of drug resistant TB.
The primary objective of this study aims to describe the plasma drug levels of the first-line anti- tuberculosis drugs in two different pulmonary TB patient groups: (1) adults with HIV co-infection and (2) adults without HIV co-infection. The secondary objectives are to investigate the clinical, microbiological and immunological outcomes of the study participants in relation to the plasma drug level and to conduct full genome sequencing and spoligotyping of MTB strains.
Plasma drug levels from venous blood will be measured densely 13 times per day at two occasions: after the first dose on Day 1 and 6 weeks after treatment. Thereafter plasma drug levels will be measured at six hours post-dose on months 2, 3, 4, 5 and 6.
Clinical, microbiological and immunological parameters such as liver and renal function, CRP and LTA4G and sputum examination (smear microscopy, RNA PCR, culture) to monitor clinical progress will also be measured.
The analysis on the plasma drug level in relation to the clinical and microbiological outcomes will be carried out in order to describe the PK/PD of anti-TB drugs and clinical, microbiogical and immunological outcomes in consideration of any possible factors that would influence the relationship between them.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Studying the Blood Levels of First-line Anti-tuberculosis Drugs in Relation to Treatment Outcomes Among Newly Diagnosed Adults With Pulmonary Tuberculosis on the Thai-Myanmar Border |
| Actual Study Start Date : | July 7, 2015 |
| Estimated Primary Completion Date : | February 2018 |
| Estimated Study Completion Date : | February 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 2HRZE/4HR
2HRZE/4HR
Adults will be treated with fixed dose combination (FDC) tablets containing: Intensive phase (content per tablet) Isoniazid -75 mg, Rifampicin - 150 mg, Pyrazinamide - 400 mg, Ethambutol - 275 mg Continuation phase (content per tablet) Isoniazid 150 mg Rifampicin 300 mg *Drug dosing will be adjusted by patient body weight. |
Drug: Isoniazid (H) Drug: Rifampicin (R) Drug: Pyrazinamide (Z) Drug: Ethambutol (E) |
- Plasma drug levels of Rifampicin [ Time Frame: 6 Months ]Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in different study groups
- Plasma drug levels of Isoniazid [ Time Frame: 6 Months ]
- Plasma drug levels of Pyrazinamide [ Time Frame: 6 Months ]
- Plasma drug levels of Ethambutol [ Time Frame: 6 Month ]
- Time to negativity of M. tuberculosis [ Time Frame: 6 Months ]Time to negativity of M. tuberculosis in relation to drug
- Genotyping MTB strains [ Time Frame: 6 Months ]Genotyping MTB strains in order to see any infection with new wild MTB or mutant strain in the study population
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Clinical and microbiogical diagnosis of pulmonary TB
- Males and females aged >18 years old
- Willing to comply with study procedures including residing in the TB centre or nearby for six months
- Written informed consent provided by participant
Exclusion Criteria:
- TB treatment in the past
- Known or suspected pregnancy
- Enrolled for TB treatment at one of the study sites
- Known hypersensitivity/intolerance to one or more of anti-TB drugs
- The MTB strain that shown resistant to Rifampicin, which is the precursor marker of MDR TB detected by a MTB/Rif Xpert Assay
-
Biochemistry test result:
- Creatinine > 3 x upper limit of normal (ULN)
- bilirubin > 2.5 x ULN
- AST and/or ALT > 5 x ULN
- Refuse to take HIV testing
- The diagnosed TB patients who choose to take the treatment at a Thai hospital or a hospital in Myanmar
- The proven non-TB patients by clinical and microbiological diagnosis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02457208
| Contact: Dr. Thomas Pouplin, PhD | 66 2 203 6333 | thomas@tropmedres.ac | |
| Contact: Professor Francois Nosten, MD, PhD | +66 5 554 5021 | francois@tropmedres.ac |
| Thailand | |
| Shoklo Malaria Research Unit | Recruiting |
| Mae Sot, Tak, Thailand, 63110 | |
| Contact: Francois Nosten, MD,PhD | |
| Responsible Party: | University of Oxford |
| ClinicalTrials.gov Identifier: | NCT02457208 History of Changes |
| Other Study ID Numbers: |
SMRU1407 |
| First Posted: | May 29, 2015 Key Record Dates |
| Last Update Posted: | October 10, 2017 |
| Last Verified: | October 2017 |
Keywords provided by University of Oxford:
|
pharmacokinetics |
Additional relevant MeSH terms:
|
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Rifampin Isoniazid Pyrazinamide Ethambutol Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Leprostatic Agents |
Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP2C8 Inducers Cytochrome P-450 CYP2C19 Inducers Cytochrome P-450 CYP2C9 Inducers Cytochrome P-450 CYP3A Inducers Fatty Acid Synthesis Inhibitors Hypolipidemic Agents Antimetabolites Lipid Regulating Agents |